{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:09:55Z","timestamp":1792706995458,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40264-025-01559-0","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T08:21:20Z","timestamp":1750666880000},"page":"1103-1118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Uncovering Pregnancy Exposures in Pharmacovigilance Case Report Databases: A Comprehensive Evaluation of the VigiBase Pregnancy Algorithm"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-5244","authenticated-orcid":false,"given":"Lovisa","family":"Sandberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1619-3751","authenticated-orcid":false,"given":"Sara Hedfors","family":"Vidlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-8960","authenticated-orcid":false,"given":"Levente","family":"K-P\u00e1pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-0849","authenticated-orcid":false,"given":"Ruth","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3946-3340","authenticated-orcid":false,"given":"Boukje C.","family":"Raemaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2604-2810","authenticated-orcid":false,"given":"Henric","family":"Taavola-Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2360-7174","authenticated-orcid":false,"given":"Annette","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5779-5066","authenticated-orcid":false,"given":"Lucy","family":"Quirant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4394-3431","authenticated-orcid":false,"given":"Tomas","family":"Bergvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2681-2226","authenticated-orcid":false,"given":"Magnus","family":"Wallberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6447-8415","authenticated-orcid":false,"given":"Johan","family":"Ellenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"2","key":"1559_CR1","doi-asserted-by":"publisher","first-page":"e004365","DOI":"10.1136\/bmjopen-2013-004365","volume":"4","author":"A Lupattelli","year":"2014","unstructured":"Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014;4(2):e004365.\u00a0https:\/\/doi.org\/10.1136\/bmjopen-2013-004365.","journal-title":"BMJ Open"},{"issue":"1","key":"1559_CR2","doi-asserted-by":"publisher","first-page":"51.e1","DOI":"10.1016\/j.ajog.2011.02.029","volume":"205","author":"AA Mitchell","year":"2011","unstructured":"Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976\u20132008. Am J Obstet Gynecol. 2011;205(1):51.e1-51.e8.\u00a0https:\/\/doi.org\/10.1016\/j.ajog.2011.02.029.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"1559_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/cpt.2981","volume":"114","author":"MM Werler","year":"2023","unstructured":"Werler MM, Kerr SM, Ailes EC, et al. Patterns of prescription medication use during the first trimester of pregnancy in the United States, 1997\u20132018. Clin Pharmacol Ther.\u00a02023;114(4):836-844.\u00a0https:\/\/doi.org\/10.1002\/cpt.2981.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1559_CR4","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/aogs.14805","volume":"103","author":"M\u00d8 Thunbo","year":"2024","unstructured":"Thunbo M\u00d8, Vendelbo JH, Witte DR, et al. Use of medication in pregnancy on the rise: study on 1.4 million Danish pregnancies from 1998 to 2018. Acta Obstet Gynecol Scand.\u00a02024;103(6):1210-1223.\u00a0https:\/\/doi.org\/10.1111\/aogs.14805.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"1559_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/ajmg.c.30313","volume":"157C","author":"MP Adam","year":"2011","unstructured":"Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet.\u00a02011;157C(3):175-182.\u00a0https:\/\/doi.org\/10.1002\/ajmg.c.30313.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"9","key":"1559_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/pds.3495","volume":"22","author":"PG Thorpe","year":"2013","unstructured":"Thorpe PG, Gilboa SM, Hernandez-Diaz S, et al. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiol Drug Saf.\u00a02013;22(9):1013-1018.\u00a0https:\/\/doi.org\/10.1002\/pds.3495.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1559_CR7","unstructured":"World Health Organization. Official records of the World Health Organization, No. 128, Sixteenth World Health Assembly, Geneva, 7\u201323 May 1963, Part II: p. 295."},{"key":"1559_CR8","unstructured":"Uppsala Monitoring Centre. A global collaboration for patient safety. https:\/\/who-umc.org\/about-the-who-programme-for-international-drug-monitoring\/about-the-who-pidm\/. Accessed 8 Aug 2024."},{"issue":"5","key":"1559_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Inf Jl.\u00a02008;42(5):409-419.\u00a0https:\/\/doi.org\/10.1177\/009286150804200501.","journal-title":"Drug Inf Jl."},{"key":"1559_CR10","unstructured":"International Council for Harmonisation off Technical Requirements for Pharmaceuticals for Human Use. Implementation guide for electronic transmission of individual case safety reports (ICSRs): E2B(R3) data elements and message specification. 2016. https:\/\/ich.org\/page\/e2br3-individual-case-safety-report-icsr-specification-and-related-files. Accessed 13 Aug 2024."},{"issue":"5","key":"1559_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-023-01291-7","volume":"46","author":"JL Richardson","year":"2023","unstructured":"Richardson JL, Moore A, Bromley RL, et al. Core data elements for pregnancy pharmacovigilance studies using primary source data collection methods: recommendations from the IMI ConcePTION Project. Drug Saf.\u00a02023;46(5):479-491.\u00a0https:\/\/doi.org\/10.1007\/s40264-023-01291-7.","journal-title":"Drug Saf"},{"key":"1559_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40264-023-01384-3","volume":"47","author":"G Favre","year":"2023","unstructured":"Favre G, Richardson JL, Moore A, et al. Improving data collection in pregnancy safety studies: towards standardisation of data elements in pregnancy reports from public and private partners, a contribution from the ConcePTION Project. Drug Saf. 2023;47(3):227-236. https:\/\/doi.org\/10.1007\/s40264-023-01384-3.","journal-title":"Drug Saf"},{"issue":"5","key":"1559_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/jac\/dkad087","volume":"78","author":"A Contejean","year":"2023","unstructured":"Contejean A, Leruez-Ville M, Treluyer J-M, et al. Assessing the risk of adverse pregnancy outcomes and birth defects reporting in women exposed to ganciclovir or valganciclovir during pregnancy: a pharmacovigilance study. J Antimicrob Chemother.\u00a02023;78(5):1265-1269.\u00a0https:\/\/doi.org\/10.1093\/jac\/dkad087.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1559_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/cancers15010173","volume":"15","author":"R Noseda","year":"2022","unstructured":"Noseda R, M\u00fcller L, Bedussi F, et al. Immune checkpoint inhibitors and pregnancy: analysis of the VigiBase\u00ae spontaneous reporting system. Cancers (Basel). 2022;15(1):173.\u00a0https:\/\/doi.org\/10.3390\/cancers15010173.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1559_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40801-021-00287-y","volume":"9","author":"T Sakai","year":"2022","unstructured":"Sakai T, Mori C, Koshiba H, et al. Pregnancy loss signal from prostaglandin eye drop use in pregnancy: a disproportionality analysis using Japanese and US spontaneous reporting databases. Drugs Real World Outcomes. 2022;9(1):43-51.\u00a0https:\/\/doi.org\/10.1007\/s40801-021-00287-y.","journal-title":"Drugs Real World Outcomes."},{"key":"1559_CR16","doi-asserted-by":"publisher","first-page":"772768","DOI":"10.3389\/fphar.2021.772768","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Yin N, Zhao Y, et al. Adverse events during pregnancy associated with entecavir and adefovir: new insights from a real-world analysis of cases reported to FDA Adverse Event Reporting System. Front Pharmacol. 2021;12:772768.\u00a0https:\/\/doi.org\/10.3389\/fphar.2021.772768.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1559_CR17","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/cid\/ciz684","volume":"70","author":"NS van De Ven","year":"2020","unstructured":"van De Ven NS, Pozniak AL, Levi JA, et al. Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy. Clin Infect Dis. 2020;70(12):2599-2606.\u00a0https:\/\/doi.org\/10.1093\/cid\/ciz684.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1559_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.vaccine.2017.11.039","volume":"36","author":"PL Moro","year":"2018","unstructured":"Moro PL, Zheteyeva Y, Barash F, et al. Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990\u20132016. Vaccine. 2018;36(1):50-54.\u00a0https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.039.","journal-title":"Vaccine"},{"key":"1559_CR19","doi-asserted-by":"publisher","first-page":"965171","DOI":"10.3389\/fimmu.2022.965171","volume":"13","author":"A Mascolo","year":"2022","unstructured":"Mascolo A, di Mauro G, Fraenza F, et al. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: the preg-co-vax study. Front Immunol. 2022;13:965171.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2022.965171.","journal-title":"Front Immunol"},{"issue":"6","key":"1559_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40264-023-01306-3","volume":"46","author":"O Mahaux","year":"2023","unstructured":"Mahaux O, Powell G, Haguinet F, et al. Identifying safety subgroups at risk: assessing the agreement between statistical alerting and patient subgroup risk. Drug Saf. 2023;46(6):601-614.\u00a0https:\/\/doi.org\/10.1007\/s40264-023-01306-3.","journal-title":"Drug Saf"},{"issue":"6","key":"1559_CR21","doi-asserted-by":"publisher","first-page":"e931","DOI":"10.1002\/hsr2.931","volume":"5","author":"S Kaundinnyayana","year":"2022","unstructured":"Kaundinnyayana S, Kamath A. Doxycycline use and adverse pregnancy or neonatal outcomes: a descriptive study using the United States Food and Drug Administration Adverse Event Reporting System database. Health Sci Rep. 2022;5(6):e931.\u00a0https:\/\/doi.org\/10.1002\/hsr2.931.","journal-title":"Health Sci Rep."},{"issue":"4","key":"1559_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.7150\/ijms.5213","volume":"10","author":"SL Hoog","year":"2013","unstructured":"Hoog SL, Cheng Y, Elpers J, Dowsett SA. Duloxetine and pregnancy outcomes: safety surveillance findings. Int J Med Sci. 2013;10(4):413-419.\u00a0https:\/\/doi.org\/10.7150\/ijms.5213.","journal-title":"Int J Med Sci"},{"issue":"7","key":"1559_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40264-021-01073-z","volume":"44","author":"A Cavadino","year":"2021","unstructured":"Cavadino A, Sandberg L, \u00d6hman I, et al. Signal detection in EUROmediCAT: identification and evaluation of medication-congenital anomaly associations and use of VigiBase as a complementary source of reference. Drug Saf. 2021;44(7):765-785.\u00a0https:\/\/doi.org\/10.1007\/s40264-021-01073-z.","journal-title":"Drug Saf"},{"issue":"10","key":"1559_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40264-020-00957-w","volume":"43","author":"L Sandberg","year":"2020","unstructured":"Sandberg L, Taavola H, Aoki Y, et al. Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase. Drug Saf. 2020;43(10):999-1009.\u00a0https:\/\/doi.org\/10.1007\/s40264-020-00957-w.","journal-title":"Drug Saf"},{"issue":"1","key":"1559_CR25","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.3346\/jkms.2024.39.e3","volume":"39","author":"D Kang","year":"2024","unstructured":"Kang D, Choi A, Park S, et al. Safety of COVID-19 vaccination during pregnancy and lactation: a VigiBase analysis. J Korean Med Sci. 2024;39(1):e3.\u00a0https:\/\/doi.org\/10.3346\/jkms.2024.39.e3.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"1559_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-024-01715-4","volume":"25","author":"R Noseda","year":"2024","unstructured":"Noseda R, Bedussi F, Gobbi C, et al. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase\u00ae. J Headache Pain. 2024;25(1):10.\u00a0https:\/\/doi.org\/10.1186\/s10194-024-01715-4.","journal-title":"J Headache Pain"},{"issue":"1","key":"1559_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40259-022-00564-4","volume":"37","author":"A Dernoncourt","year":"2023","unstructured":"Dernoncourt A, Liabeuf S, Bennis Y, et al. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization pharmacovigilance database (VigiBase\u00ae). BioDrugs. 2023;37(1):73-87.\u00a0https:\/\/doi.org\/10.1007\/s40259-022-00564-4.","journal-title":"BioDrugs"},{"issue":"3","key":"1559_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1248\/yakushi.15-00235","volume":"136","author":"T Sakai","year":"2016","unstructured":"Sakai T, Ohtsu F, Sekiya Y, et al. Methodology for estimating the risk of adverse drug reactions in pregnant women: analysis of the Japanese Adverse Drug Event Report Database [in Japanese]. Yakugaku Zasshi. 2016;136(3):499-505.\u00a0https:\/\/doi.org\/10.1248\/yakushi.15-00235.","journal-title":"Yakugaku Zasshi"},{"issue":"1","key":"1559_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12888-020-02525-z","volume":"20","author":"T Anzai","year":"2020","unstructured":"Anzai T, Takahashi K, Watanabe M, et al. Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: an approach using latent class analysis. BMC Psychiatry. 2020;20(1):118.\u00a0https:\/\/doi.org\/10.1186\/s12888-020-02525-z.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1559_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12325-017-0654-0","volume":"35","author":"A Stollenwerk","year":"2018","unstructured":"Stollenwerk A, Sohns M, Heisig F, et al. Review of post-marketing safety data on tapentadol, a centrally acting analgesic. Adv Ther. 2018;35(1):12-30.\u00a0https:\/\/doi.org\/10.1007\/s12325-017-0654-0.","journal-title":"Adv Ther"},{"issue":"11","key":"1559_CR31","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/ph16111566","volume":"16","author":"L Sportiello","year":"2023","unstructured":"Sportiello L, Di Napoli R, Balzano N, et al. Disease-modifying therapies (DMTs) in pregnant and lactating women with multiple sclerosis: analysis of real-world data from EudraVigilance database. Pharmaceuticals. 2023;16(11):1566.\u00a0https:\/\/doi.org\/10.3390\/ph16111566.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"1559_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/ard-2022-222505","volume":"82","author":"M Petri","year":"2023","unstructured":"Petri M, Landy H, Clowse MEB, et al. Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis. 2023;82(2):217-225.\u00a0https:\/\/doi.org\/10.1136\/ard-2022-222505.","journal-title":"Ann Rheum Dis"},{"key":"1559_CR33","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40264-024-01448-y","volume":"47","author":"C Zaccaria","year":"2024","unstructured":"Zaccaria C, Piccolo L, Gordillo-Mara\u00f1\u00f3n M, et al. Identification of pregnancy adverse drug reactions in pharmacovigilance reporting systems: a novel algorithm developed in EudraVigilance. Drug Saf. 2024;47(11):1127-1136.\u00a0https:\/\/doi.org\/10.1007\/s40264-024-01448-y.","journal-title":"Drug Saf"},{"key":"1559_CR34","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Appendix I (B) to the implementation guide for electronic transmission of individual case safety reports (ICSRS). Backwards and forwards compatibility recommendations. Version 2.03. 2022. https:\/\/www.ich.org\/page\/e2br3-individual-case-safety-report-icsr-specification-and-related-files. Accessed 6 Aug 2024."},{"key":"1559_CR35","unstructured":"MedDRA\u00ae. Mapping. https:\/\/www.meddra.org\/mapping. Accessed 12 June 2024."},{"issue":"5","key":"1559_CR36","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1037\/h0031619","volume":"76","author":"JL Fleiss","year":"1971","unstructured":"Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull. 1971;76(5):378-382.\u00a0https:\/\/doi.org\/10.1037\/h0031619.","journal-title":"Psychol Bull"},{"issue":"3","key":"1559_CR37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10618-006-0052-8","volume":"14","author":"GN Nor\u00e9n","year":"2007","unstructured":"Nor\u00e9n GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov. 2007;14(3):305-328.\u00a0https:\/\/doi.org\/10.1007\/s10618-006-0052-8.","journal-title":"Data Min Knowl Discov"},{"key":"1559_CR38","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module VI: collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). 2017. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-and-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf. Accessed 22 Aug 2024."},{"key":"1559_CR39","unstructured":"MedDRA\u00ae. Term selection: points to consider. Endorsed guide for MedDRA users. Release 4.24. 2024. https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/001006_termselptc_r4_24_mar2024.pdf. Accessed 5 Nov 2024."},{"key":"1559_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40264-023-01389-y","volume":"47","author":"YRJ van Rijt-Weetink","year":"2024","unstructured":"van Rijt-Weetink YRJ, Egberts TCG, van Hunsel FPAM, et al. Validation of a novel method to assess the clinical quality of information in pregnancy-related pharmacovigilance case reports: a ConcePTION project. Drug Saf. 2024;47(3):261-270.\u00a0https:\/\/doi.org\/10.1007\/s40264-023-01389-y.","journal-title":"Drug Saf"},{"key":"1559_CR41","doi-asserted-by":"publisher","first-page":"1187888","DOI":"10.3389\/fdsfr.2023.1187888","volume":"3","author":"YRJ Van Rijt-Weetink","year":"2023","unstructured":"Van Rijt-Weetink YRJ, Chamani K, Egberts ACG, et al. Elements to assess the quality of information of case reports in pregnancy pharmacovigilance data: a ConcePTION project. Front Drug Saf Regul. 2023;3:1187888. https:\/\/doi.org\/10.3389\/fdsfr.2023.1187888.","journal-title":"Front Drug Saf Regul."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01559-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01559-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01559-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T13:52:07Z","timestamp":1757512327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01559-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1559"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01559-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"8 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no financial support for the research, authorship and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lovisa Sandberg, Sara Hedfors Vidlin, Levente K-P\u00e1pai, Ruth Savage, Boukje C. Raemaekers, Henric Taavola-Gustafsson, Annette Rudolph, Lucy Quirant, Tomas Bergvall, Magnus Wallberg and Johan Ellenius have no conflicts of interest that are directly\u00a0related to the content of this article. Ruth Savage is an Editorial Board member of Drug Safety. She was not involved in the selection of peer reviewers nor any of the subsequent editorial decisions. Lucy Quirant, as of May 2023, is no longer employed by the Uppsala Monitoring Centre. However, her contributions to the study were completed prior to the time of departure, as part of her employment at the Uppsala Monitoring Centre.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable. This study did not use personal data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are not publicly available. Access to the data is restricted based on the conditions for access within the WHO Programme for International Drug Monitoring. Subject to these conditions, data are available from the authors on reasonable request. For further inquiries, please contact Uppsala Monitoring Centre via .The VigiBase pregnancy algorithm is implemented in VigiLyze, the tool for searching and analysing VigiBase data, which is available to national pharmacovigilance centres as members of the WHO Programme for International Drug Monitoring. An initial version of the algorithm was implemented in November 2022. The version evaluated in the study, which includes some minor updates, was implemented in February 2024. VigiBase data, including output of the VigiBase pregnancy algorithm, are also available through VigiBase Custom Searches.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The code used for this study is not provided. The implementation of the VigiBase Pregnancy Algorithm in R will be made available at .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by LS, SHV, LK-P, HT and RS. Manual annotations were performed by LS, AR, BCR and RS. The first draft of the manuscript was written by LS, SHV, LK-P and RS, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}